Clinical trials: psoriasis
Psoriasis Vulgaris, Topical Administration
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of a Botanical Total Coumarin Cream (TC) in Treating Patients with Psoriasis Vulgaris
- Trial name
- PLANTCOAT-IIb (NCT03372811)
- Testing
- Total coumarin (TC) cream, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Psoriasis Research Institute of Guangzhou
Psoriasis
A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.
The purpose of this study is to assess the clinical profile of patients with moderate to severe psoriasis in Spain. The primary objective is to analyze the clinical profile of patients with moderate to severe psoriasis, as…
- Trial name
- NCT01262534
- Testing
- Clinical profile of patients, Patient Preferences about treatment, Quality of Life
- Volunteers
- 1,042 people
- Sponsor
- Janssen-Cilag, S.A.
Effects, Drug Side
An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis in order to select doses for further clinical trials.
- Trial name
- NCT05858047
- Testing
- SYHX1901
- Where
- China
- Volunteers
- 93 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Psoriasis Vulgaris
LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 22811 in healthy male subjects as well as to determine the safety and tolerability of single oral…
- Trial name
- NCT00833872
- Testing
- LEO 22811
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Brief Description of Focus of Study
A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06912165
- Testing
- WD-890 tablet
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Zhejiang Wenda Pharma Technology LTD.
Plaque Type Psoriasis
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
The aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type psoriasis.
- Trial name
- ADACCESS (NCT02016105)
- Testing
- GP2017 Adalimumab, Humira ® Adalimumab
- Where
- 79 sites in United States, Bulgaria and 2 more
- Volunteers
- 465 people
- Sponsor
- Sandoz
Psoriasis
Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
This is a multicenter, Phase 1, randomized, double-blind, placebo-controlled trial in subjects with moderate to severe psoriasis to assess the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD) and…
- Trial name
- NCT02156466
- Testing
- MSB0010841
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Moderate to Severe Psoriasis
CLEAR Study: Clinical Experience Acquired With Raptiva Study
A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered Raptiva in the treatment of patients with moderate to severe psoriasis
- Trial name
- NCT00256139
- Testing
- Raptiva
- Where
- Switzerland
- Volunteers
- 793 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris
Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with: 1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream 2.
- Trial name
- NCT00216892
- Testing
- Calcipotriol, (calcipotriol + betamethasone)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 1,032 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the…
- Trial name
- NCT01188928
- Testing
- Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene
- Where
- 59 sites in United States
- Volunteers
- 1,152 people
- Sponsor
- LEO Pharma
Psoriasis
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The purpose of this study is to investigate the safety and efficacy of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Trial name
- NCT03022045
- Testing
- risankizumab
- Where
- 9 sites in Japan
- Volunteers
- 18 people
- Sponsor
- AbbVie
Psoriasis
Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).
HRO350 contains an oil-based extract from herring roe (Clupea harengus) in soft capsules and contains phospholipids (complex lipids) which are naturally rich in marine polyunsaturated fatty acids.
- Trial name
- HeROPA (NCT06125808)
- Testing
- HRO350
- Where
- 49 sites in Finland, Germany and 3 more
- Volunteers
- 521 people
- Sponsor
- Arctic Bioscience
Plaque Psoriasis
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
- Trial name
- CLARITY (NCT02826603)
- Testing
- Secukinumab, Ustekinumab
- Where
- 154 sites in United States, Canada and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Participants With Moderate-To-Severe Plaque Psoriasis
The purpose of this study is to achieve a better understanding of clinical characteristics, treatment patterns and clinical outcomes of participants with moderate-to-severe plaque psoriasis (PsO) as well as their unmet medical…
- Trial name
- NCT05547490
- Where
- 2 sites in China
- Volunteers
- 3,506 people
- Sponsor
- Bristol-Myers Squibb
Osteoarthritis, Psoriasis
Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis
The purpouse of this study is to determine the efficacy and safety of chondroitin sulphate conventional treatment in patients with both knee osteoarthritis and plaque psoriasis.
- Conditions
- Osteoarthritis, Psoriasis, Joint Diseases, Muskuloskeletal Diseases
- Trial name
- NCT00669123
- Testing
- Chondroitin sulphate
- Where
- 2 sites in Spain
- Volunteers
- 126 people
- Sponsor
- Bioiberica
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
- Trial name
- BeSeen (NCT07219420)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Canada and 11 more
- Volunteers
- 320 people
- Sponsor
- UCB Biopharma SRL
Chronic Plaque-type Psoriasis
Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis
A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients.
- Trial name
- NCT01828086
- Testing
- CJM112, Secukinumab
- Where
- 18 sites in United States
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Skin Disease, Immune System Disease
A Study of HL40626S Tablets in Healthy Adults
This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and…
- Conditions
- Skin Disease, Immune System Disease, Skin Diseases, Papulosquamous, Psoriasis (PsO)
- Trial name
- NCT07736586
- Testing
- HL40626S tablets
- Where
- 2 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- HighsLab Therapeutics Inc.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
- Trial name
- ENDURE (NCT01090310)
- Testing
- AIN457
- Where
- 35 sites in United States, Brazil and 6 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.